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Genome-wide association study identifies multiple
risk loci for renal cell carcinoma
Ghislaine Scelo et al.#
Previous genome-wide association studies (GWAS) have identified six risk loci for renal cell
carcinoma (RCC). We conducted a meta-analysis of two new scans of 5,198 cases and 7,331
controls together with four existing scans, totalling 10,784 cases and 20,406 controls
of European ancestry. Twenty-four loci were tested in an additional 3,182 cases and
6,301 controls. We confirm the six known RCC risk loci and identify seven new loci at 1p32.3
(rs4381241, P¼ 3.1 10 10), 3p22.1 (rs67311347, P¼ 2.5 108), 3q26.2 (rs10936602,
P¼ 8.8 109), 8p21.3 (rs2241261, P¼ 5.8 109), 10q24.33-q25.1 (rs11813268,
P¼ 3.9 108), 11q22.3 (rs74911261, P¼ 2.1 10 10) and 14q24.2 (rs4903064,
P¼ 2.2 10 24). Expression quantitative trait analyses suggest plausible candidate genes at
these regions that may contribute to RCC susceptibility.
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K
idney cancer is the seventh most commonly diagnosed
cancer in more developed regions of the world and
incidence rates have been rising1,2. Renal cell carcinoma
(RCC) comprises over 90% of kidney cancers and clear cell
renal cell carcinoma (ccRCC) is the major histological subtype
(B80% of RCC cases)3. Direct evidence for inherited
predisposition to RCC is provided by a number of rare cancer
syndromes with defined germline mutations in 11 genes
(BAP1, FLCN, FH, MET, PTEN, SDHB, SDHC, SDHD, TSC1,
TSC2 and VHL), that are associated with the development of
different RCC subtypes4,5. While identification of these genes has
led to important insights into the pathogenesis of RCC5,6, even
collectively these diseases account for only a very small portion of
the twofold increased risk of RCC seen in first-degree relatives of
RCC patients7,8. Support for polygenic susceptibility to RCC has
come from genome-wide association studies (GWAS) that have
identified single-nucleotide polymorphisms (SNPs) at six loci
influencing RCC risk in populations of European ancestry at
chromosome bands 2p21, 2q22.3, 8q24.21, 11q13.3, 12p11.23
and 12q24.31 (refs 9–14). Here, we present findings from a
meta-analysis of six GWAS scans of RCC; two new scans of 5,198
cases and 7,331 controls were combined with four previously
published scans of 5,586 cases and 13,075 controls9–11, reaching a
total of 10,784 cases and 20,406 controls, all of European ancestry.
Twenty-four promising loci were further tested in an independent
replication set of 3,182 cases and 6,301 controls drawn from three
independent series (Fig. 1).
Results
Discovery-phase findings. For both the GWAS and replication
sets, cases were restricted to invasive RCC (International
Classification of Disease for Oncology second and third Edition
topography code C64), including all histological subtypes,
diagnosed in adults (that is, Zaged 18 years) (Supplementary
Table 1). Comparable sample and SNP quality control exclusions
were applied to the two new genotyped scans (Supplementary
Online methods), which used the OmniExpress and Omni5M
arrays, respectively. The discovery phase was conducted as a
fixed-effect meta-analysis that included these two new scans
together with four previously published scans (IARC-1, NCI-1,
MDA and UK). The four previously reported scans were
conducted using HumanHap 300 and 610 for IARC-1; 500 and
660w for NCI-1; 660w for MDA; and OmniExpress and
HumanHap 1.2M for UK. Imputations were performed on
all scans using 1,094 subjects from the 1000 Genomes Project
(phase 1 release 3) as the reference panel (Supplementary Online
methods). Each discovery-stage data set was analysed individually
assuming log-additive (trend) SNP effects, with the exception
of the two IARC scans which were pooled and analysed together
(Supplementary Online methods). We then performed a fixed-
effects meta-analysis of 7,437,091 SNPs that were polymorphic in
at least two data sets. Quantile–quantile plots of the combined
results showed little evidence for inflation of the test statistics
compared to the expected distribution (l¼ 1.034; Supplementary
Fig. 1). For visual representation, we provide a Manhattan plot
summarizing the genome-wide SNP results in Supplementary
Fig. 2.
In the meta-analysis, we observed associations that surpassed
the level of genome-wide significance for all six of the previously
reported GWAS loci at 2p21, 2q22.3, 8q24.21, 11q13.3, 12p11.23
and 12q24.31 (Supplementary Table 2). We did not find evidence
to support a previously suggested locus marked by rs3845536 at
1q24.1 (ref. 15) (meta-analysis P¼ 0.0062).
For replication, we selected 24 SNPs marking 20 possible
new-risk regions, based on a P value o5.0 10 7. We also
included two SNPs at the known 2p21 RCC risk locus that
were potentially independent from the previously reported
genome-wide significant SNPs in that region9,16. Four
additional SNPs representing four promising loci (one of which
was among the 20 previously mentioned regions) were also
advanced from an analysis restricted to ccRCC (5,649 cases,
15,011 controls) based on the aforementioned P value criterion
(Supplementary Data 1). For genotyping these markers using
Taqman assays, highly correlated proxy variants were substituted
for 14 SNPs for which a Taqman assay could not be optimized;
two proxies per variant were selected for two SNPs in the region
where the smallest P values were found. Thus, a total of 32 SNPs
from 24 regions were genotyped and passed quality control
metrics in three independent series totalling 3,182 cases and
6,301 controls (Fig. 1, Supplementary Table 3, Supplementary
Data 1, Supplementary Online methods).
Seven new loci associated with RCC risk. In the combined
analysis, SNPs at seven loci showed evidence for an association
with RCC which was genome-wide significant: 1p32.3 (rs4381241,
P¼ 3.1 10 10), 3p22.1 (rs67311347, P¼ 2.5 10 8),
3q26.2 (rs10936602, P¼ 8.8 10 9), 8p21.3 (rs2241261,
P¼ 5.8 10 9), 10q24.33-q25.1 (rs11813268, P¼ 3.9 10 8),
11q22.3 (rs74911261, P¼ 2.1 10 10) and 14q24.2 (rs4903064,
P¼ 2.2 10 24) (Table 1, Supplementary Data 1). None of
SNP associations showed between study heterogeneity. Regional
LD plots for each locus are detailed in Supplementary Fig. 3.
Restricting the analyses to ccRCC, no additional SNPs with
genome-wide significant associations were identified (Suppleme-
ntary Data 1).
We conducted further analyses of the genome-wide significant
SNPs stratifying by sex and three established RCC risk factors:
body mass index, smoking and hypertension (Supplementary
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Figure 1 | Overview of the study design. The six genotyping scans
contributing to the meta-analysis are detailed on the left, with number of
cases and controls and arrays used for the genotyping. The meta-analysis
was performed after imputations on 7,437,091 SNPs. Boxes in italic bold
represent genotype data newly generated for this study.
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Fig. 4). The most notable difference in risk was observed for the
14q24 variants that had a stronger effect in women than in men
[for rs4903064, odds ratios: ORs (95% confidence interval: CI) of
1.36 (1.28–1.45) and 1.13 (1.08–1.19), respectively; heterogeneity
P¼ 7.4 10 6]. Other observed differences across strata
were of smaller magnitude (Supplementary Fig. 4). No notable
findings were observed in additional SNP analyses of non-clear
cell histologic subtypes (papillary, chromophobe; Supplementary
Data 1) and case age at onset (o60 versus 60þ ) (Supplementary
Data 2). For SNP rs76912165, which was not genome-wide
significant overall, a trend for higher risk associated with stage 1
cases was observed (Supplementary Data 2).
We investigated whether rs6706003 and rs6755594 defined
independent signals at the previously reported 2p21 locus.
rs6706003 is minimally correlated with rs7579899 (r2¼ 0.11 in
CEU)17 that was identified in the initial GWAS9, and moderately
correlated with rs12617313 (r2¼ 0.61), which was identified in a
previous fine-mapping analysis16. By comparison, the correlation
of rs6755594 with both of these sites is notably weaker (r2¼ 0.04
and 0.08, respectively). In conditional analyses of the GWAS data
adjusting for rs7579899 and rs12617313, the rs6706003 signal was
substantially reduced (OR 1.07, P¼ 0.05), while the rs6755594
signal was partially attenuated (OR 1.07, P¼ 4.0 10 4). On the
basis of these findings, there is insufficient evidence to conclude
that rs6755594 marks an independent locus in this region.
Newly identified loci and biological inferences. To investigate
plausible candidate variants and genes among the newly
discovered loci for further study, we: (1) fine-mapped each locus,
using 1000 Genome Phase 1, version 3 data (Supplementary
Data 3); (2) screened non-coding annotation from ENCODE
data using HaploReg v4.1 (ref. 18) and RegulomeDB v1.2 (ref. 19)
to identify possible functional variants, primarily in cells of
non-kidney origin but also in BC_kidney_01-11002 and
BC_kidney_H12817N cell lines (Supplementary Data 3); and
(3) performed expression quantitative trait locus (eQTL) analyses
with genes located up to 3Mb around the newly identified risk
markers (or highly correlated proxies) using ccRCC and normal
kidney tissue data from the Cancer Genome Atlas [Kidney Renal
Clear Cell Carcinoma (KIRC) collection; 481 tumour and 71
normal tissue samples]20 and IARC (555 tumour and 234 normal
tissue samples)21 (Supplementary Data 4).
The new highly significant locus marked by rs4903064 at 14q24
maps to the double PHD fingers 3 gene (DPF3), which encodes a
histone acetylation and methylation reader of the BAF and PBAF
chromatin remodelling complexes. This locus contains a set of
correlated SNPs (r240.8 in 1000G EUR) that reside within the
introns of DPF3 (Supplementary Data 3), of which only
rs4903064 itself is annotated as likely to disrupt transcription
factor binding (RegulomeDB scoreo4)19. This variant is located
within a region annotated as an enhancer in multiple tissues by
the RoadMap project22 and is predicted to alter IRX2/IRX5
binding motifs. In an eQTL analysis, we observed a consistent
pattern of increased DPF3 expression associated with
the rs49030604 risk allele in both the KIRC and IARC data
sets (P¼ 5.5 10 8 and 3.8 10 9, respectively, Fig. 2,
Supplementary Data 4). A consistent, but statistically weaker,
expression pattern in the normal kidney tissue data sets of more
limited sample size was also observed (P¼ 0.15 and 0.42,
respectively). It is noteworthy that 14q24 is deleted in 22–45%
of ccRCC20,23. While DPF3 mutation is rare in RCC20, somatic
alterations of BAP1 and PBRM1, components of the BAF
and PBAF complexes, respectively, are commonly seen in
ccRCC24. In this regard, deregulation of this pathway is a
common feature of RCC, and these data suggest that rs4903064
may play a role in RCC development through dysregulation of the
DPF3 expression.
For the 1p32.3 locus marked by rs4381241, an intronic SNP
within FAS-associated factor 1 (FAF1) that encodes a protein that
can initiate or enhance FAS-mediated apoptosis, we identified
several promising correlated variants with RegulomeDB scores,
suggesting alteration of transcription factor binding (Supplemen-
tary Data 3) but did not observe a strong effect on expression
(Supplementary Data 4). FAS-associated factor 1 facilitates
the degradation of b-catenin, a transcriptional co-activator
that stimulates expression of genes driving cell proliferation25.
Constitutively activated b-catenin, induced by VHL inactivation,
is an important pathway in ccRCC oncogenesis26. The rs4381241
risk allele is weakly correlated (r2¼ 0.12 in CEU) with the allele of
another FAF1 variant (rs17106184) associated with reduced risk
of type-2 diabetes and lower serum insulin post oral glucose
challenge27,28.
The risk variant rs67311347 maps to a region of 3p22.1 that
harbours several genes. Within the KIRC tumour tissue data, the
risk-associated allele of the surrogate SNP rs9821249 (r2¼ 0.97
with rs67311347 in CEU) was weakly associated with higher
expression of CTNNB1 (P¼ 0.03). This gene, located 706 kb away
centromeric, is a strong candidate as it encodes the RCC proto-
oncogene b–catenin, although this association was not seen
within the IARC data set. In both normal tissue data sets, the risk-
associated allele of rs67311347 was associated with a higher
expression of ZNF620 (P¼ 0.03 and 0.02). This gene encodes the
Zinc finger protein 620, but the function of this protein has not
been well described.
The 8p21.3 risk variants rs2241261 and rs2889 (used as proxy
for rs2241260, P¼ 1.6 10 9, r2¼ 0.61 with rs2241261 in CEU;
Supplementary Data 1) are located 0.9 and 1.7 kb respectively from
TNFRSF10B, a tumour suppressor gene encoding a mediator of
apoptosis signalling29. In both the KIRC and IARC tumour tissue
data (P¼ 0.002 and 0.03, respectively), the rs2241261 risk allele was
associated with a decreased expression of GFRA2, which encodes
for cell-surface receptor for glial cell line-derived neurotrophic
factor (GDNF) and neurturin (NTN), and mediates activation
of the RET tyrosine kinase receptor (Glial cell line-derived
neurotrophic factor (Supplementary Data 4). A potential link
with renal tissue function has not been described. Of the variants in
strong LD with either rs2241261 or rs2889 (r240.8 in 1000G
EUR), only rs2889 is annotated as a strong regulatory candidate by
RegulomeDB, predicted to be in a strong enhancer region and
altering motifs for FOX family members of transcription factors
(Supplementary Data 3).
SNPs rs74911261 and rs1800057 are located 214 kb apart on
11q22.3 and are highly correlated (r2¼ 0.83 in CEU)
non-synonymous variants, but for separate genes; rs74911261
(P144L) maps to KDELC2, which encodes a protein localizing
to the endoplasmic reticulum, while rs1800057 (P1054R) maps
to the DNA repair gene ATM. The functional prediction
tools SIFT30 and PolyPhen-2 (ref. 31) suggest that both amino
acid substitutions are damaging. It is also plausible that they
are correlated with regulatory variants that influence expression of
nearby genes. In eQTL analyses, no consistent associations
were detected. Only one of the five variants with strong LD to
rs74911261 (r240.8 in 1000G EUR) has a RegulomeDB score
suggesting likely disruption of transcription factor binding
(scoreo4), rs141379009, and is located within a region annotated
as an enhancer by the Roadmap project and predicted to alter a
consensus Zfp105/ZNF35 binding motif (Supplementary Data 3).
ATM mutations in RCC are uncommon20,23, and ataxia
telangiectasia patients, though at markedly elevated cancer risk,
have not been reported to frequently develop RCC32, questioning a
direct role of ATM in RCC susceptibility.
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For the remaining two new RCC risk loci, in silico analyses and
eQTL did not indicate altered regulation of a plausible candidate
gene. For each of these loci, we identified SNPs that correlate with
low RegulomeDB scores for intriguing nearby candidate genes
(Supplementary Data 3). The marker SNP rs10936602 maps to
3q26.2, a region amplified in 15% of ccRCC tumours in KIRC20;
several notable nearby genes could represent possible candidate
genes, including MECOM, a transcriptional regulator frequently
amplified in RCC20, and TERC, encoding a component of
telomerase, in which mutations cause autosomal dominant
dyskeratosis congenita and aplastic anaemia33. This risk variant is
moderately correlated with variants previously associated with
telomere length and risk of several malignancies, including multiple
myeloma, chronic lymphocytic leukaemia, bladder cancer, glioma
and colorectal cancer (rs10936599, rs12696304, rs1920116; r2¼ 0.66,
0.58 and 0.80, respectively)34–39. The 10q24 risk variant rs11813268
is located 4 kb upstream of OBFC1, a gene identified in GWAS and
laboratory investigation as a regulator of human telomere length40.
This risk variant is highly correlated with SNPs associated with
leucocyte telomere length (rs4387287, rs9419958 and rs9420907;
r2¼ 0.99, 0.82 and 0.82, respectively)40, and to a lesser degree with
melanoma (rs2995264, r2¼ 0.52)41, suggesting the underlying basis
for RCC risk may be mediated through a common pathway.
Polygenic risk score analysis and explained heritability.
Additional analyses were conducted by generating a polygenic
risk score (PRS) from 13 SNPs mapping to the six previously
reported and seven newly identified susceptibility loci (Suppleme-
ntary Table 5). Accepting the caveat of the winner’s curse
phenomenon, whereby the strength of SNP associations may
have been overestimated, subjects in the highest decile of the PRS
had a threefold increased risk of RCC relative to the lowest decile
(OR 3.24, 95% CI 2.86–3.67; P¼ 1.2 10 76). Stratifying by
histological subtypes, the PRS was most strongly associated with
clear cell RCC (per unit increase: OR 3.24, 95% CI 2.91–3.62;
P¼ 3.4 10 100), with a weaker association for chromophobe
RCC (OR 2.34, 95% CI 1.58–3.46; P¼ 3.4 10 5) and papillary
RCC (OR 1.83, 95% CI 1.44–2.32; P¼ 5.3 10 7). The PRS
did not significantly differ between cases aged o60 versus 60þ
at diagnosis or across cancer stage (Supplementary Table 5).
Using Genome-Wide Complex Trait Analysis (GCTA), we
estimate that the heritability and familial relative risk of RCC
attributable to all common variation were 14.2% (SE¼ 0.023) and
1.52 (SE¼ 0.10), respectively. After excluding established
and newly identified loci, the estimates were 12.8% (SE¼ 0.023)
and 1.46 (SE¼ 0.10), respectively. On the basis of these estimates,
B90% of the heritability and familial risk remains to be elucidated.
Discussion
Our meta-analysis of six GWAS scans identified seven new RCC
susceptibility loci. Our findings provide further evidence for
polygenic susceptibility to RCC. Future investigation of the genes
targeted by the risk SNPs is likely to yield increased insight into
the development of RCC. We estimate that the risk loci so far
identified for RCC account for only about 10% of the familial
risk of RCC. Although the power of our study to detect the
major common loci (MAF40.2) conferring risk Z1.2 was high
(B80%), we had low power to detect alleles with smaller effects
and/or MAFo0.1. By implication, variants with such profiles
probably represent a much larger class of susceptibility loci
for RCC and hence a large number of variants remain to
be discovered. In parallel, whole-exome and whole-genome
sequencing of genetically enriched cases selected according to
early age of onset or family history would provide new
Table 1 | Summary results for newly discovered loci associated with renal cell carcinoma.
Locus SNP* Closest
gene
Position
(base pairs)
A/aw MAFz Statistics Discovery
(10,784 cases;
20,406 controls)
Replication
(3,182 cases;
6,301 controls)
Combined
(13,966 cases;
26,707 controls)
1p32.3 rs4381241 FAF1 50907438 T/C 0.44 OR (95% CI) 1.11 (1.07–1.15) 1.11 (1.03–1.20) 1.11 (1.07–1.15)
P 1.1 108 8.7 10 3 3.1 10 10
I2 17% 0% 0%
3p22.1 rs67311347 40533243 G/A 0.31 OR (95% CI) 0.89 (0.86–0.93) 0.94 (0.88–1.01) 0.90 (0.87–0.94)
P 4.7 10 8 8.8 10 2 2.5 108
I2 0% 56% 20%
3q26.2 rs10936602 LRRIQ4 169536637 T/C 0.27 OR (95% CI) 0.90 (0.86–0.94) 0.91 (0.85–0.98) 0.90 (0.87–0.93)
P 2.7 10 7 9.7 10 3 8.8 10 9
I2 0% 48% 11%
8p21.3 rs2241261 RHOBTB2/
TNFRSF10B
22876739 C/T 0.51 OR (95% CI) 1.10 (1.06–1.14) 1.10 (1.03–1.17) 1.10 (1.06–1.13)
P 3.5 10 7 2.0 10 2 5.8 109
I2 3% 58% 21%
10q24.33-
q25.1
rs11813268 OBFC1 105682296 C/T 0.16 OR (95% CI) 1.13 (1.08–1.19) 1.10 (1.01–1.19) 1.12 (1.07–1.17)
P 5.1 10 7 2.1 10 2 3.9 10 8
I2 32% 0% 0%
11q22.3 rs74911261 KDELC2 108357137 G/A 0.02 OR (95% CI) 1.42 (1.26–1.61) 1.38 (1.12–1.69) 1.41 (1.27—1.57)
P 2.1 108 2.6 10 3 2.1 10 10
I2 0% 0% 0%
rs1800057 ATM 108143456 C/G 0.02 OR (95% CI) 1.40 (1.24–1.59) 1.30 (1.04–1.62) 1.38 (1.23–1.53)
P 1.1 10 7 2.2 10 2 9.0 109
I2 14% 0% 0%
14q24.2 rs4903064 DPF3 73279420 T/C 0.23 OR (95% CI) 1.18 (1.13–1.23) 1.30 (1.21–1.39) 1.21 (1.16–1.25)
P 1.1 10 14 2.6 10 12 2.2 10 24
I2 28% 0% 36%
*SNP with lowest P value within locus. For 11q22.3, results shown for two non-synonymous SNPs in KDELC2 (rs74911261, Pro144Leu) and ATM (rs1800057, Pro1054Arg; r2¼0.83 in CEU).
wA, common allele; a, minor allele.
zMinor allele frequency among all controls (n¼ 26,707). Odds ratios (OR) are shown for the minor allele, assuming a log-additive (trend) SNP effect.
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opportunities to discover rare variants associated with RCC.
As more RCC susceptibility alleles are discovered, deciphering
the biological basis of risk variants should provide new insights
into the biology of RCC that may lead to new approaches to
prevention, early detection and therapeutic intervention.
Methods
Informed consent and study approval. Each participating study obtained
informed consent from the study participants and approval from its Institutional
Review Board (for the IARC scans and replication: IARC Ethics Committee; for the
MDA scans and replication: Institutional Review Board of The University of Texas
MD Anderson Cancer Center; for the UK scan: Royal Marsden NHS Trust ethics
committee; for the NCI scans: NCI Special Studies Institutional Review Board,
The Vanderbilt Institutional Review Board, the Emory University Institutional
Review Board, Dana-Farber/Harvard Cancer Center institutional review board,
Institutional Review Board of the Harvard T.H. Chan School of Public Health,
Institutional Review Board of Brigham and Women’s Hospital, Van Andel
Research Institute Institutional Review Board, Spectrum Health Institutional
Review Board and Fred Hutchinson Cancer Research Center Institutional Review
Board; for the Mayo replication: Mayo Clinic institutional review board.
Genome-wide SNP genotyping. Genome-wide SNP genotyping for two new scans
was coordinated by the National Cancer Institute (NCI-2; NCI, Bethesda, Maryland,
USA) and the International Agency for Research on Cancer (IARC-2; IARC, Lyon,
France). The NCI-2 samples, obtained from 13 studies conducted in the US and
Finland (Supplementary Table 1), were genotyped at the NCI Cancer Genomics
Research Laboratory (CGR, Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland, USA) using the Illumina OmniExpress array.
The NCI-2 scan included controls previously genotyped by Illumina OmniExpress,
or Omni 2.5Marray from some of the participating studies (ATBC, CPSII, HPFS,
NHS, PLCO and WHI; Supplementary Table 1). IARC-2 samples, obtained from six
studies conducted in Europe and Australia (Supplementary Table 1), were genotyped
at the Centre National de Genotypage, Commissariat a` l’e´nergie atomique et aux
e´nergies alternatives (CNG, CEA, Evry and Paris) using the Illumina Omni 5M
arrays. Additional controls (N¼ 447) from one study (IARC K2) were also included,
which had been genotyped on the OmniExpress array at Johns Hopkins Center
for Inherited Disease Research.
Quality control assessment. The quality control exclusions for the four
previously published scans have been reported9–11. For the two new scans, quality
control was conducted separately at each institution using comparable exclusions.
For the new IARC-2 scan, a total of 5,424 samples were genotyped on the
Illumina Omni5 chip. Samples were excluded sequentially based on the following
criteria: heterozygosity rate (n¼ 14, 0.3%), relatedness (n¼ 7, 0.1%), non-CEU
ancestry (n¼ 37, 0.7%), sex discrepancy (n¼ 20, 0.4%), genotyping success rate
o95% (n¼ 14, 0.3%) and unexpected duplicates (n¼ 22, 0.4%). After adding the
447 previously scanned controls (OmniExpress array) from the IARC K2 study,
using the above-listed criteria we excluded 22 samples (4.9%) and, due to
unexpected duplicates or first-degree relatedness between the two scans, an
additional 11 (2.5%) samples from this scan and three samples from the Omni5
scan. From the Omni5 scan, genotypes for 4,276,196 SNPs were obtained, of which
we excluded 127,523 SNPs because of low (o95%) success rate, 14,513 SNPs
for departure from Hardy–Weinberg disequilibrium (HWE) (Po10 7) in
controls, 65,300 with ambiguous strand issues, and 37,319 non-autosomal SNPs.
The final Omni5 analytical data set included 4,031,541 SNPs on 2,781 cases and
2,526 controls. For the same criteria, the 951,117 SNPs obtained from the
OmniExpress array were pruned from 16,409, 1,132, 24,370 and 20,715 SNPs,
respectively, leaving a final data set of 888,491 SNPs on 414 controls. Imputation of
genotypes was performed on these data sets after the exclusion of 2,485,185 SNPs
from the Omni5, and 742 SNPs from the OmniExpress scans, when minor allele
frequency (MAF) was o0.05.
For the new NCI-2 scan, a total of 3,168 samples were initially genotyped by the
OmniExpress array. A total of 22,775 (3%) SNPs with call rate o90% were
excluded, as were 282 samples (9%) with completion rateo94%. After this
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median, whiskers extend to the minimum of either the data range or 1.5 times the interquartile range and statistical outliers are plotted as points.
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exclusion, the concordance rate was 499.9% for 66 pairs of blind duplicate pairs.
After removing duplicates, a data set including 2,820 unique samples was advanced
to further assess quality control at the subject level. In addition, we excluded
10 sex-discordant individuals and two individuals with excessively low mean
heterozygosity for ChrX SNPs. For the cleaned data including genotypes for 2,808
individuals, we next pooled in a total of 4,221 previously scanned controls
(HumanOmni2.5M or HumanOmniExpress array) from the ATBC, CPSII, HPFS,
NHS, PLCO and WHI studies (Supplementary Table 1). After merging the newly
scanned data with the previously scanned controls, we obtained genotypes for
7,029 individuals. Subsequently, we excluded data for 204 non-CEU individuals
(admixture proportion for CEUo80%), both members of a pair of unexpected
within-study duplicate samples, one from each of eight unexpected cross-study
duplicate pairs, and one from each of eight related pairs (two parent–child
pairs and six sibling pairs). The final analytic data comprised 6,808 individuals
(2,417 cases, 4,391 controls) for 678,580 loci.
Statistical analysis. The statistical analysis included summary data from four
previously published scans conducted at the NCI (NCI-1)9, IARC (IARC-1)9, the
University of Texas MD Anderson Cancer Center (MDA)10, and the Institute of
Cancer Research, UK (UK)11, as well as the two new scans from NCI (NCI-2) and
IARC (IARC-2). The IARC-1 and IARC-2 data were pooled, resulting in five separate
discovery-stage data sets. Imputation was performed separately for each scan data set
using SNPs of minor allele frequency Z0.01 (Z0.05 for the IARC data set), with
1000 Genomes Project data (phase 1 release 3) used as a reference set. IMPUTE2
version 2.2.2 was used for imputation of the NCI-1, NCI-2, MDA and UK data sets,
while Minimac version 3 was used for the IARC data set42,43. Imputed SNPs with
sufficient accuracy as assessed by r2Z0.3 for both IMPUTE2 and Minimac were
retained for the analysis. We further assessed the quality of imputation by randomly
selecting 10% of genotyped SNPs on chromosome 1 within the IARC-1 series (which
used the least-dense chip across the different scans) and removing them before
running the imputation algorithm. MAFs calculated from the genotyping data
correlated with r2 40.99 with MAFs calculated from the imputed dosage data.
Finally, top SNPs were technically validated through Taqman genotyping in the
IARC and NCI-2 scan (Supplementary Table 4). After imputation, genotypes for
7,437,091 SNPs were available for analysis.
Association testing with RCC was conducted separately for each data set
assuming log-additive (trend) SNP effects using SNPTEST version 2.2 at NCI and
R version 3.2.3 at IARC. The model covariates varied by data set; for the previous
scans, we used the same covariates as in the initially published analyses. The
covariates were as follows: sex and study for NCI-1 (no statistically significant
eigenvectors present in null model); sex and four significant eigenvectors for
NCI-2; age, sex and two significant eigenvectors for MDA; no covariates for the
UK; and sex, study, and 19 significant eigenvectors for IARC-1 and IARC-2.
Eigenvectors were considered significant if Po0.05 from the Tracy–Widom
statistics. In the IARC series, all 19 eigenvectors were significantly associated with
the country of recruitment. We additionally conducted analyses restricted to
ccRCC. The SNP association results from each data set were combined by
meta-analysis using a fixed-effects model. Heterogeneity in genetic effects across
data sets was assessed using the I2 and Cochran’s Q statistics.
Analysis of heritability. We estimated GWAS heritability, hl2, using the GCTA
software44,45 and data from the NCI-1 and NCI-2 scans. Analyses assumed a disease
prevalence of 1.66%, included only SNPs with MAF40.05, removed subjects missing
more than 5% of genotypes and adjusted for sex, substudy and the top 20 eigenvectors.
In addition to quality control steps taken for the original GWAS, we removed SNPs
with a missing rate 410% or a HWE P value o10 5 in the control group in any
study. To estimate heritability attributable to undiscovered loci, we identified 21 SNPs
that were associated with renal cancer (Po5.0 10 8) and removed all SNPs within
250 kb of those loci before calculation of the genetic relation matrix. After subject
exclusions, data from 3,609 cases and 7,524 controls were included in the heritability
analysis. Familial relative risk was estimated by established methods46.
Replication genotyping and analysis. After filtering out previous GWAS-iden-
tified SNPs, we selected for replication 32 SNPs with association P values
o5.0 10 7. A separate set of 3,182 cases and 6,301 controls of European
ancestry were genotyped at three institutions (IARC: 1,674 cases and 4,222
controls; Mayo Clinic: 909 cases and 1,479 controls; MDA: 599 cases and
600 controls) for replication. Genotyping at IARC and MDA was conducted by
Taqman assay (Applied Biosystems, CA, USA), while the Mayo Clinic samples
were genotyped using a combination of MassARRAY (Agena Bioscience, Inc., CA,
USA) and Taqman assays. The associations with each SNP (per minor allele/trend)
were computed individually for each institution (IARC: adjusted for sex and
study; Mayo Clinic: age and sex; MDA: age and sex) and combined with the
discovery-stage results through fixed-effects meta-analysis.
Polygenic risk score and analyses of additional RCC phenotypes. PRS was
calculated for 13 SNPs, one from each of the six previously identified loci and seven
newly identified RCC risk loci (rs7105934, rs4765623, rs718314, rs11894252,
rs12105918, rs6470588, rs4381241, rs67311347, rs10936602, rs2241261,
rs11813268, rs74911261 and rs4903064), as follows:
PRSi ¼
X13
j¼1
wjxij;
where PRSi is the risk score for individual i, xij is the number of risk alleles for the
jth variant and wj is the weight [ln(OR)] of the jth variant. Associations with the
PRS and individual SNPs selected for replication were computed for the following
RCC phenotypes: papillary and chromophobe RCC histologies (through
case-control analyses); age at onset (o60 versus 60þ years at diagnosis; case-only
analyses) and stage (2, 3 and 4 versus 1; case-only analyses). The stage-stratified
analyses were restricted to the IARC data sets, for which these data were available.
Technical validation of imputed SNPs. To technically validate our imputation
findings, we genotyped the 32 SNPs carried over for replication by Taqman assay in
a subset of samples from the NCI-2 and IARC-1/2 scans (n¼ 566 and 6,402
respectively). The concordances between imputed and directly assayed genotypes
are detailed in Supplementary Table 4.
Gene expression data and eQTL analysis. KIRC: Genotyping and RNAseq data
for the KIRC TCGA samples (481 tumours and 71 normal renal tissues) were
downloaded from The Cancer Genome Atlas database (http://cancergenome.nih.gov/,
accessed on 15 January 2016). We quantified expression as normalized read counts
and removed outlier samples with expression values exceeding 1.5 times the inter-
quartile range. Linear trend tests were used to test for allele-specific increases in gene
expression for genes within a 6Mb window. Analyses were performed using R v3.1.
IARC: For a subset of cases from the IARC K2 and the CE studies
(Supplementary Table 1), gene expression analysis of renal normal and tumour
tissue samples were conducted using Illumina HumanHT-12 v4 expression
BeadChips (Illumina, Inc., San Diego) for samples with RNA integrity (RIN)45.0.
Raw expression intensities of samples with signal-to-noise ratio 49.5 were
processed with variance-stabilizing transformation and quantile normalization
with lumi package47 as reported by Wozniak et al.21. The 50 mer sequences of
probes were mapped to human reference genome hg19 downloaded from UCSC
Genome Browser database (http://genome.ucsc.edu/, accessed on 15 November
2014) using BWA48 to demarcate positional relationships between corresponding
probes/genes and SNPs. In total, 234 normal and 555 tumour tissue samples from
confirmed clear cell RCC cases with available genotyping data were used to test for
allele-specific increases in gene expression for genes within a 6Mb window under
linear trend assumption. Analyses were performed using R v3.1.3.
Data availability. The scan IARC-2 obtained Institutional Review Board
certification permitting data sharing in accordance with the US NIH Policy for
Sharing of Data Obtained in NIH Supported or Conducted GWAS. Data are
accessible on dbGaP (study name: ‘Pooled Genome-Wide Analysis of Kidney
Cancer Risk (KIDRISK)’; url: http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs001271.v1.p1). Similarly, the NCI-1 scan is accessible on
dbGaP (phs000351.v1.p1). Data from IARC-1 and MDA scans are available from
Paul Brennan and Xifeng Wu, respectively, upon reasonable request. The UK scan
data will be made available on the European Genome-phenome Archive database
(accession number: EGAS00001002336). The NCI-2 scan will be posted on dbGaP.
TCGA data were accessed at the following url: https://gdc-portal.nci.nih.gov/
projects/TCGA-KIRC.
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